MedTrace Logo

Mobile Application for Gastroesophageal Reflux Disease

NCT07744815 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-08-05

No results posted yet for this study

Summary

Gastroesophageal reflux disease (GERD) is a chronic condition with frequent symptom recurrence that may negatively affect sleep quality and quality of life. This randomized controlled study aims to evaluate whether a mobile application developed as a mobile application, combined with standard education and diaphragmatic breathing training, can reduce symptom recurrence and improve sleep quality and quality of life in patients with GERD. Participants will be randomly assigned to either an intervention group receiving the mobile application or a control group receiving standard education. Outcomes will be assessed using the GerdQ, Reflux Symptom Index (RSI), GERD-HRQL, and Insomnia Severity Index (ISI) at baseline, 2 weeks, 4 weeks, and 8 weeks.

Conditions

  • Gastroesophageal Reflux Esophagitis

Interventions

BEHAVIORAL

Study Mobile Application

Participants receive a study mobile application providing gastroesophageal reflux disease education, lifestyle modification guidance, dietary recommendations, diaphragmatic breathing exercises, and reminder messages for 4 weeks.

BEHAVIORAL

Standard Education

Participants receive standard education for gastroesophageal reflux disease.

Sponsors & Collaborators

  • Fooyin University

    lead OTHER

Principal Investigators

  • Yi-Hsuan Liu, Nurse Practitioner · Fooyin University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-15
Primary Completion
2026-02-16
Completion
2026-02-16

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07744815 on ClinicalTrials.gov